Department of Urology, National Defense Medical College, Tokorozawa, Japan.
Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
Anticancer Res. 2021 Dec;41(12):5987-5996. doi: 10.21873/anticanres.15417.
BACKGROUND/AIM: Simultaneous inhibition of histone deacetylase and proteasomes induces endoplasmic reticulum (ER) stress efficiently. RTS-V5 is the first dual histone deacetylase-proteasome inhibitor, and we anticipated that combining it with the cytochrome P450 family 3 subfamily A member 4 inhibitor ritonavir would enhance its activity in bladder cancer cells.
Using bladder cancer cells (human T-24, J-82, murine MBT-2), we evaluated the ability and mechanism by which the combination of RTS-V5 and ritonavir induced ER stress and killed cancer cells.
The combination of RTS-V5 and ritonavir triggered robust apoptosis and inhibited bladder cancer growth effectively in vitro and in vivo. It caused ubiquitinated protein accumulation and induced ER stress synergistically. The combination inhibited the mammalian target of rapamycin pathway by increasing the expression of AMP-activated protein kinase. We also found that the combination caused histone and tubulin hyperacetylation.
Ritonavir enhances the ability of RTS-V5 to cause ER stress in bladder cancer cells.
背景/目的:同时抑制组蛋白去乙酰化酶和蛋白酶体可有效地诱导内质网(ER)应激。RTS-V5 是首个双重组蛋白去乙酰化酶-蛋白酶体抑制剂,我们预计将其与细胞色素 P450 家族 3 亚家族 A 成员 4 抑制剂利托那韦联合使用将增强其在膀胱癌细胞中的活性。
使用膀胱癌细胞(人 T-24、J-82、鼠 MBT-2),我们评估了 RTS-V5 和利托那韦联合使用诱导 ER 应激和杀死癌细胞的能力和机制。
RTS-V5 和利托那韦的联合使用在体外和体内均能有效引发强烈的细胞凋亡并抑制膀胱癌的生长。它协同导致泛素化蛋白积累并诱导 ER 应激。该联合通过增加 AMP 激活的蛋白激酶的表达抑制哺乳动物雷帕霉素靶蛋白途径。我们还发现该联合导致组蛋白和微管蛋白乙酰化过度。
利托那韦增强了 RTS-V5 在膀胱癌细胞中诱导 ER 应激的能力。